US 12,465,600 B2
Pediatric suspension formulation
Dennis Mark Mcdaid, Dublin (IE); Damien Patrick Flynn, Dublin (IE); and Maurice Joseph Anthony Clancy, Dublin (IE)
Assigned to Xeolas Pharmaceuticals Ltd., Dublin (IE)
Filed by Xeolas Pharmaceuticals Ltd., Dublin (IE)
Filed on Mar. 13, 2023, as Appl. No. 18/182,797.
Application 18/182,797 is a continuation of application No. 17/061,630, filed on Oct. 2, 2020, granted, now 11,826,359.
Claims priority of provisional application 63/062,785, filed on Aug. 7, 2020.
Claims priority of provisional application 62/911,689, filed on Oct. 7, 2019.
Claims priority of provisional application 62/911,035, filed on Oct. 4, 2019.
Prior Publication US 2023/0390266 A1, Dec. 7, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4439 (2006.01); A61J 1/00 (2023.01); A61K 9/00 (2006.01); A61K 9/16 (2006.01); A61K 47/02 (2006.01); A61K 47/14 (2017.01); A61K 47/26 (2006.01); A61K 47/36 (2006.01)
CPC A61K 31/4439 (2013.01) [A61J 1/00 (2013.01); A61K 9/0053 (2013.01); A61K 9/1652 (2013.01); A61K 47/02 (2013.01); A61K 47/14 (2013.01); A61K 47/26 (2013.01); A61K 47/36 (2013.01)] 32 Claims
OG exemplary drawing
 
1. A storage-stable omeprazole system, the system comprising (i) a first mixture comprising (a) a therapeutically effective amount of omeprazole, or a pharmaceutically acceptable salt thereof, (b) optionally a first desiccant, and (c) optionally a first buffering agent, wherein the first mixture contains a percentage of moisture of no more than about 2.5%; and (ii) a second mixture comprising a second buffering agent, wherein the second mixture contains a percentage of moisture of no more than about 2.5%, wherein the first mixture and the second mixture are stored separately from each other and are mixed together on or just before constitution with water, and wherein the system contains no sodium from a sodium-containing buffering agent or the system contains sodium and potassium at a ratio of from about 1:2.6 to about 1:3.4 by weight.